EIF4A3 and non-small cell lung carcinoma: EIF4A3 inhibition not only reduces tumor proliferation, migration, and angiogenesis, but it also shortens the half-life of VEGFA, suggesting that LINC00667-VEGFA-EIF4A3 is an oncogenic pathway in NSCLC.